A5044544447- Diabetes Treatment and Management
- Atrial Fibrillation Management and Outcomes
- Infective Endocarditis Diagnosis and Management
- Chronic Kidney Disease and Diabetes
- Cardiac Arrest and Resuscitation
- Cardiac Structural Anomalies and Repair
- Potassium and Related Disorders
- Heart Failure Treatment and Management
- Mechanical Circulatory Support Devices
- Venous Thromboembolism Diagnosis and Management
- Transplantation: Methods and Outcomes
- Cardiovascular Health and Risk Factors
- Long-Term Effects of COVID-19
- Cardiac electrophysiology and arrhythmias
- Parkinson's Disease Mechanisms and Treatments
- Takotsubo Cardiomyopathy and Associated Phenomena
- Cannabis and Cannabinoid Research
- Cardiac tumors and thrombi
- Erythropoietin and Anemia Treatment
- Autopsy Techniques and Outcomes
- Antiplatelet Therapy and Cardiovascular Diseases
- Systemic Lupus Erythematosus Research
- Employment and Welfare Studies
- Acute Myocardial Infarction Research
- Cardiovascular Effects of Exercise
SUNY Upstate Medical University
2021-2025
Upstate University Hospital
2024
State University of New York
2021
Withdrawal Statement “This manuscript has been withdrawn by the authors as it was submitted and made public without full consent of all authors. Therefore, do not wish this work to be cited reference for project. A revised version will in future. If you have any questions, please contact corresponding author.”
Objective N -methyl- d -aspartate (NMDA) receptor antagonism in the central nervous system has been described. More data are needed regarding its clinical impact on cardiovascular system. In this study, we assess of NMDA with amantadine patients primary or secondary parkinsonism. Methods To conduct retrospective cohort analysis, queried TriNetX Global database January 13, 2024 to identify 18 years old older Parkinsonism between 2003 and December 2023 divided them into 2 groups based use. We...
Background: Electrophysiology (EP) procedures have revolutionized the management of arrhythmias, improving survival and overall outcomes. However, limited data exists evaluating long-term outcomes different EP in underrepresented racial ethnic groups. Methods: We utilized from TriNetX US collaborative network included adult participants who underwent between 2013-2023 to create two cohorts: non-Hispanic Black White participants. Propensity score matching (PSM) was performed using predefined...
Background: Maternal cardiovascular health during and after pregnancy is influenced by various factors, including personal family support. However, the specific impact of abnormal support on maternal outcomes remains understudied. Methods: Utilizing TriNetX global research network within US Collaborative Network, we investigated influence (ICD10CM:Z63) one year post-pregnancy. Cohort 1 comprised women aged 15 to 60 with documented problems relating primary or childbirth between 2008 2023. 2...
Background: Patients with chronic kidney disease stage 5 (CKD-5) face heightened risks of cardiovascular (CV) complications and mortality. Glucagon-like peptide-1 agonists (GLP-1a), primarily used in type 2 diabetes, are being investigated for potential CV benefits this population. This study aims to evaluate the impact GLP-1a treatment on outcomes survival among CKD-5 patients. Methods: retrospective cohort utilized data adult patients diagnosed between January 2014 August 2023 from TriNetX...
Background: Maternal cardiovascular health is a critical concern, particularly during and following pregnancy. Previous studies have highlighted the influence of social determinants on outcomes, but specific impact adverse Physical Environment, Housing, Economic Conditions maternal remains underexplored. Methods: Using TriNetX global research network within US Collaborative Network, we explored how (ICD10CM: Z58 ICD10CM: Z59) pregnancy one year postpartum. Using, propensity score matching...
Background: Heart failure (HF) and paroxysmal atrial fibrillation (AF) are major causes of morbidity mortality, each exacerbating the other leading to poorer outcomes. Glucagon-like peptide-1 agonists (GLP-1a), primarily used for glycemic control in type 2 diabetes, may offer cardiovascular benefits patients with concurrent HF AF. Objective: This study aims evaluate impact GLP-1a on clinical outcomes Methods: retrospective utilized data from 51,446 HFrEF across 91 global healthcare...
Background: Heart failure (HF) represents a critical public health concern, especially among women of childbearing age, where its prevalence has been steadily increasing over recent years. Women with prior adverse pregnancy outcomes, such as hypertensive disorders pregnancy, gestational diabetes mellitus, or preterm birth, face an elevated risk developing heart later in life. Methods: This study investigated and trends the period 2013 to 2023, leveraging data from 64 healthcare organizations...
Background: Heart failure is a leading cause of morbidity and mortality globally, heart transplantation remains definitive treatment for end-stage failure. Previous studies have suggested potential gender disparities in access to outcomes transplantation, but comprehensive analyses using large datasets are limited. Objective: This study aims investigate transplant among patients the National Inpatient Sample (NIS) dataset. Methods: Using NIS dataset (2017-2020), we analyzed data from 11,025...
Introduction: The utilization of direct oral anticoagulant (DOAC) agents for atrial fibrillation (AF) in individuals with end-stage renal disease (ESRD) has increased despite a lack robust supportive data from randomized controlled trials. We planned to assess the outcomes associated rivaroxaban versus warfarin ESRD population AF. Methods: utilized TriNetX Global Collaborative Network, which includes 114 Healthcare organizations perform propensity-score matched retrospective cohort study....
Background: Disparities in healthcare outcomes between rural and urban populations are well-documented, yet limited research specifically addresses differences heart transplant for failure patients. Methods: We conducted a retrospective cohort study using the NIS dataset (2017-2020), analyzing 11,025 patients who received transplants. The included 565 10,460 examined variables such as age, gender, hospital bed size, race, insurance status, comorbidities. Primary in-hospital mortality,...
Background: Serotonin-norepinephrine reuptake inhibitors (SNRIs) inhibit the presynaptic of serotonin and norepinephrine are widely used in treatment depression neuropathic pain. Some studies suggest that use SNRIs may play a role etiology takotsubo cardiomyopathy. Objectives: We aim to evaluate impact serotonin-norepinephrine on clinical outcomes patients with Method: The authors retrospectively analyzed deidentified patient data from TriNetX research network. Patients aged ≥18 years...
Background: High prevalence of psychiatric disorders (PD) is seen in Takotsubo cardiomyopathy (TC). Existing literature presents conflicting results but often identifies worse outcomes patients with PD who develop TC. Primary limitations those studies were relatively small sample sizes and insufficient matching for confounders. Therefore, we used a global database to determine differences TC without PD. Methods: We queried the TriNeTX Global collaborative network adults diagnosed between...